Abstract 167P
Background
The study aimed to evaluate baseline and dynamic changes of serum neutrophil-to-lymphocyte ratio (NLR) level as biomarkers of response to anti-PD-1/PD-L1 blockade combined with anti-VEGF or tyrosine kinase inhibitors (TKIs) in advanced hepatocellular carcinoma (aHCC) patients and the potential relationship between NLR and serum cytokines.
Methods
We collected NLR level at baseline and week 3 since initial treatment as well as baseline serum cytokines in patients with aHCC treated with immune-targeted combination therapy from October 2018 to November 2021. The cutoff of baseline NLR was defined by median level. We defined both baseline NLR ≤ 2.63 as well as NLR decrease at week 3 as group1 (n = 30), baseline NLR ≤ 2.63 while NLR increase at week 3 as group2 (n = 27), baseline NLR > 2.63 while NLR decrease at week 3 as group3 (n = 38), both baseline NLR>2.63 as well as NLR increase at week 3 as group4 (n = 14).
Results
A total of 132 patients with aHCC received the immune-targeted combination therapy were included. Baseline high NLR was significantly associated with worse progression-free survival (PFS) (5.4 vs. 14.1 months, p < 0.001) and overall survival (OS) (11.3 vs. 27.7 months, p < 0.001), even after multivariate analysis. NLR level decreased significantly at week 3 in patients with complete response or partial response (CR/PR) (baseline vs. week3: 2.30 vs. 1.96, p = 0.006), no significant difference was shown in patients with progression disease (PD) (n = 18) (baseline vs. week3: 3.80 vs. 2.90, p = 0.157). Patients in group4 showed the worst treatment response, with no patients achieved CR/PR. Cytokines analysis showed that patients with baseline high NLR had significantly higher level of baseline serum IL-8 than those with low NLR (5.66 vs. 2.05 pg/ml, p = 0.001). Patients with baseline high IL-8 showed worse PFS (5.5 vs. 11.4 months, p =0.047) and OS (13.5 vs. 26.4 months, p = 0.001).
Conclusions
NLR is an independent prognostic factor for aHCC, the combination of dynamic change and baseline NLR may assist in screening out patients who are difficult to benefit from immune-targeted therapy. High baseline NLR may correlate with high baseline serum IL-8.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The CAMS Innovation Fund for Medical Sciences; The Translational Research Project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences; Beijing Natural Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract